JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Michael D. Wattenbarger, Executive Vice President and Chief Information Officer at Addus HomeCare Corp (NASDAQ:ADUS), has sold 343 shares of the company’s common stock. The shares were sold at a price of $99.71 each, amounting to a total transaction value of $34,200. The transaction comes as the stock trades near $96.75, down about 15% over the past week, with InvestingPro data showing the stock in oversold territory.
Following this transaction, which occurred on February 25, 2025, Wattenbarger holds 9,841 shares in the company. The sale was conducted under a previously established 10b5-1 plan, primarily to meet tax obligations related to the vesting of restricted stock awards granted by Addus HomeCare. Despite recent market pressure, InvestingPro analysis indicates the company maintains a GOOD financial health score, with sufficient cash flows to cover debt obligations. For deeper insights into insider trading patterns and 10+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Addus HomeCare Corporation reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $1.38 against a forecast of $1.35. Revenue also exceeded projections, reaching $297.1 million compared to the anticipated $284.28 million. Despite this positive financial performance, Addus HomeCare’s stock experienced a decline, reflecting investor concerns over broader market conditions and potential Medicaid policy changes. The company completed a significant acquisition of Gentiva, which is expected to bolster its market presence. KeyBanc Capital Markets maintained an Overweight rating on Addus HomeCare, highlighting strong growth in its Personal Care segment and the benefits of the Gentiva acquisition. Stephens also retained an Overweight rating but adjusted the price target to $142, citing Addus HomeCare’s robust mergers and acquisitions strategy. Meanwhile, Raymond (NSE:RYMD) James reduced its price target to $120, maintaining an Outperform rating, noting the company’s strong balance sheet and free cash flow generation. These developments indicate a mixed sentiment among investors and analysts, driven by uncertainties in Medicaid funding and legislative changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.